- The stock price of Aptinyx (NASDAQ: APTX) increased by over 4% pre-market. This is why it happened.
The stock price of Aptinyx (NASDAQ: APTX) – a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders – increased by over 4% pre-market. Investors appear to be responding to the company announcing that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies. And the company anticipates reporting data from this study in the second half of 2022.
“We are pleased to be moving forward in evaluating NYX-458 in patients suffering from cognitive impairment. Current therapies for these patients often do not deliver meaningful benefits and there is a great need for new therapeutic options. We believe the mechanism of NYX-458 is uniquely suited to address the cognitive deficits experienced by these patients and we look forward to building on the compelling preclinical data we have garnered with NYX-458 to date.”
— Norbert Riedel, Ph.D., chief executive officer of Aptinyx
“Misfolded alpha-synuclein deposition can lead to NMDA glutamate receptor dysfunction and contribute to cognitive deficits that characterize patients with Parkinson’s disease dementia and dementia with Lewy bodies. Modulation of NMDA glutamate receptors to address this underlying disease pathology is a compelling approach to treating the broad spectrum of symptoms associated with cognitive impairment. I look forward to seeing the data from this study, which offers a first step in understanding the potential for NYX-458 as a novel therapeutic option.”
— Peter LeWitt M.D., Professor of Neurology at Wayne State University School of Medicine
Disclaimer: This article is intended for informational purposes. Prior to making any investment, you should conduct your own analysis and financial strategy.